UCI scientists identify lesion-healing mechanism in psoriasis

October 27, 2014

A UC Irvine-led study has revealed the underlying genetic factors that help repair skin lesions caused by psoriasis, which could engender new methods of controlling the lingering condition.

Dr. Bogi Andersen, professor of biological chemistry and endocrinology at UCI, and colleagues discovered that a gene called grainyhead - known to be important in epidermal development and wound healing - triggers a repair pathway for psoriasis lesions. Conversely, they found that deletion of this gene increased the severity and longevity of the disfiguring patches.

"Our research suggests that targeting this mechanism of healing may lead to pharmaceutical products that limit the itchy, painful lesions all psoriasis sufferers must endure," Andersen said. Study results appear online Oct. 27 in The Journal of Clinical Investigation.

Psoriasis is a chronic skin condition caused by an overactive immune system in which immune cells secrete inflammatory mediators that cause thickening and other abnormalities in the epidermis, the outermost layer of the skin. These lesions look like scaly plaques, and they heal at a rate dependent upon the severity of the disease.

The researchers learned that in psoriasis a compound called grainyhead-like 3 - which binds to DNA to control the rate of transcription of genetic information from DNA to messenger RNA - orchestrates the activation of an epidermal repair pathway. (The grainyhead gene was initially discovered in fruit flies, where it's important for wound healing.)

They also found it easier to induce psoriasis-like lesions in mice lacking the GRHL3 gene. Furthermore, these lesions did not resolve properly and persisted even in the face of active immune suppression treatments currently being studied for the disease.

"Our study indicates that an evolutionarily ancient epidermal repair pathway is activated in psoriasis lesions and that this pathway suppresses disease severity and helps heal the lesions," Andersen said. "We speculate that abnormalities in this pathway might contribute to disease severity and that in the future this mechanism could be targeted to help treat psoriasis."
William Gordon, Michael Zeller, Rachel Klein, Hsiang Ho, Francisco Espitia and Pierre Baldi of UCI and William Swindell and Johann Gudjonsson of the University of Michigan contributed to the study, which was supported by the National Institutes of Health (grants AR44882, T32-HD60555 and 1F32AR065356-01A1 and grants K08AR060802, LM010235 and LM07443), the National Science Foundation (grant IIS-0513376), the Irving Weinstein Foundation, the National Psoriasis Foundation, the A. Alfred Taubman Medical Research Institute, the Doris Duke Charitable Foundation and an American Skin Association Carson Research Scholar Award in Psoriasis.

University of California - Irvine

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.